Digital Therapeutics Seminar Series: Part II
The marriage of healthcare and software has led to the emergence of digital therapeutics (Dtx), a nascent area of digital health that has the potential to improve patient care and deliver better clinical outcomes. And, with an increased focus on telehealth and disruptive methods of delivering care accelerated by the COVID-19 pandemic, the Dtx market is estimated to soar to more than $5 billion by 2027.
Life sciences and technology companies are looking at Dtx as a way to deliver value, but unlocking this potential will require they navigate a number of regulatory and market challenges. Join Foley Hoag for a two-part webinar series exploring the current legal and regulatory landscape, the future of the Dtx market, and the key considerations for new and existing manufacturers.
Download program materials here.
Part II - Business & IP Considerations
How can companies prepare for funding, structure collaborations and explore exit strategies, all while protecting their intellectual property and user data? In the second part of this series, our attorneys will explore:
- Licensing and collaboration considerations and best practices
- Equity and debt financing issues for Dtx ventures
- Patent eligibility challenges, as well as overall patent and trade secret strategies
- David Broadwin, Partner, Foley Hoag, LLP
- Hemmie Chang, Partner, Co-Chair, Life Sciences Group; Chair, Licensing & Strategic Alliances Practice, Foley Hoag LLP
- Thomas Draper, Partner, Co-Chair, Debt Finance Practice, Foley Hoag LLP
- Erik Huestis, Partner, Registered Patent Attorney, Foley Hoag LLP